Phase I study of elliptinium (2-n-methyl-9-hydroxyellipticinium)

Avi Israel Einzig, Richard J. Gralla, Brian R. Leyland-Jones, David P. Kelsen, Irene Cibas, Ellen Lewis, And Ernest Greenberg

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Elliptinium (2-N-methyl-9-hydroxyellipticinium), a chemotherapeutic agent whose mechanism of action has not been completely elucidated, intercalates into DNA. In this Phase I clinical trial, the schedule of drug administration consisted of weekly intravenous infusions. Twenty-nine patients were evaluable for toxicity. The initial dose level was 40 mg/m2 and was escalated to 150 mg/m2 through six levels. The dose-limiting side effects were emesis, xerostomia, and azotemia. The lack of myelosuppression was the most striking feature. Objective responses (partial remission, minor response) were seen in one patient each with Hodgkin's disease, non-Hodgkin's lymphoma, breast cancer, and nasopharyngeal carcinoma. We recommend a Phase II evaluation of elliptinium at a dose of 100 mg/m2 on a weekly schedule.

Original languageEnglish (US)
Pages (from-to)235-241
Number of pages7
JournalCancer Investigation
Volume3
Issue number3
DOIs
StatePublished - 1985
Externally publishedYes

Fingerprint

elliptinium
Drug Administration Schedule
Breast Neoplasms
Azotemia
Xerostomia
Clinical Trials, Phase I
Hodgkin Disease
Intravenous Infusions
Non-Hodgkin's Lymphoma
Vomiting
Appointments and Schedules
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Einzig, A. I., Gralla, R. J., Leyland-Jones, B. R., Kelsen, D. P., Cibas, I., Lewis, E., & Greenberg, A. E. (1985). Phase I study of elliptinium (2-n-methyl-9-hydroxyellipticinium). Cancer Investigation, 3(3), 235-241. https://doi.org/10.3109/07357908509039784

Phase I study of elliptinium (2-n-methyl-9-hydroxyellipticinium). / Einzig, Avi Israel; Gralla, Richard J.; Leyland-Jones, Brian R.; Kelsen, David P.; Cibas, Irene; Lewis, Ellen; Greenberg, And Ernest.

In: Cancer Investigation, Vol. 3, No. 3, 1985, p. 235-241.

Research output: Contribution to journalArticle

Einzig, AI, Gralla, RJ, Leyland-Jones, BR, Kelsen, DP, Cibas, I, Lewis, E & Greenberg, AE 1985, 'Phase I study of elliptinium (2-n-methyl-9-hydroxyellipticinium)', Cancer Investigation, vol. 3, no. 3, pp. 235-241. https://doi.org/10.3109/07357908509039784
Einzig, Avi Israel ; Gralla, Richard J. ; Leyland-Jones, Brian R. ; Kelsen, David P. ; Cibas, Irene ; Lewis, Ellen ; Greenberg, And Ernest. / Phase I study of elliptinium (2-n-methyl-9-hydroxyellipticinium). In: Cancer Investigation. 1985 ; Vol. 3, No. 3. pp. 235-241.
@article{94edc348aed7413c97949d4576d051d2,
title = "Phase I study of elliptinium (2-n-methyl-9-hydroxyellipticinium)",
abstract = "Elliptinium (2-N-methyl-9-hydroxyellipticinium), a chemotherapeutic agent whose mechanism of action has not been completely elucidated, intercalates into DNA. In this Phase I clinical trial, the schedule of drug administration consisted of weekly intravenous infusions. Twenty-nine patients were evaluable for toxicity. The initial dose level was 40 mg/m2 and was escalated to 150 mg/m2 through six levels. The dose-limiting side effects were emesis, xerostomia, and azotemia. The lack of myelosuppression was the most striking feature. Objective responses (partial remission, minor response) were seen in one patient each with Hodgkin's disease, non-Hodgkin's lymphoma, breast cancer, and nasopharyngeal carcinoma. We recommend a Phase II evaluation of elliptinium at a dose of 100 mg/m2 on a weekly schedule.",
author = "Einzig, {Avi Israel} and Gralla, {Richard J.} and Leyland-Jones, {Brian R.} and Kelsen, {David P.} and Irene Cibas and Ellen Lewis and Greenberg, {And Ernest}",
year = "1985",
doi = "10.3109/07357908509039784",
language = "English (US)",
volume = "3",
pages = "235--241",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Phase I study of elliptinium (2-n-methyl-9-hydroxyellipticinium)

AU - Einzig, Avi Israel

AU - Gralla, Richard J.

AU - Leyland-Jones, Brian R.

AU - Kelsen, David P.

AU - Cibas, Irene

AU - Lewis, Ellen

AU - Greenberg, And Ernest

PY - 1985

Y1 - 1985

N2 - Elliptinium (2-N-methyl-9-hydroxyellipticinium), a chemotherapeutic agent whose mechanism of action has not been completely elucidated, intercalates into DNA. In this Phase I clinical trial, the schedule of drug administration consisted of weekly intravenous infusions. Twenty-nine patients were evaluable for toxicity. The initial dose level was 40 mg/m2 and was escalated to 150 mg/m2 through six levels. The dose-limiting side effects were emesis, xerostomia, and azotemia. The lack of myelosuppression was the most striking feature. Objective responses (partial remission, minor response) were seen in one patient each with Hodgkin's disease, non-Hodgkin's lymphoma, breast cancer, and nasopharyngeal carcinoma. We recommend a Phase II evaluation of elliptinium at a dose of 100 mg/m2 on a weekly schedule.

AB - Elliptinium (2-N-methyl-9-hydroxyellipticinium), a chemotherapeutic agent whose mechanism of action has not been completely elucidated, intercalates into DNA. In this Phase I clinical trial, the schedule of drug administration consisted of weekly intravenous infusions. Twenty-nine patients were evaluable for toxicity. The initial dose level was 40 mg/m2 and was escalated to 150 mg/m2 through six levels. The dose-limiting side effects were emesis, xerostomia, and azotemia. The lack of myelosuppression was the most striking feature. Objective responses (partial remission, minor response) were seen in one patient each with Hodgkin's disease, non-Hodgkin's lymphoma, breast cancer, and nasopharyngeal carcinoma. We recommend a Phase II evaluation of elliptinium at a dose of 100 mg/m2 on a weekly schedule.

UR - http://www.scopus.com/inward/record.url?scp=0022256969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022256969&partnerID=8YFLogxK

U2 - 10.3109/07357908509039784

DO - 10.3109/07357908509039784

M3 - Article

VL - 3

SP - 235

EP - 241

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 3

ER -